I-Mab Announces Upcoming Participation at September Conferences

On September 8, 2020 I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported its participation in the following conferences in September (Press release, I-Mab Biopharma, SEP 8, 2020, View Source [SID1234564786]). Details of the conferences and management presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald Virtual Global Healthcare Conference 2020
Presentation: Tuesday, September 15, 2020 at 8:00-8:30 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

Webcast link: View Source

The webcast will also be available under "Event Calendar" on IMAB’s IR website at View Source

One-on-one meetings: September 15-17, 2020

For more information, please contact your Cantor Fitzgerald representative.

Jefferies Virtual Asia Forum
Presentation: Wednesday, September 16, 2020 at 4:00-4:50 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 14-16, 2020

For more information, please contact your Jefferies representative.

ICBCI Virtual ADR New Economy Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 18, 2020

For more information, please contact your ICBCI representative.

2020 Huatai USA Autumn Virtual China Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 21-23, 2020

For more information, please contact your Huatai representative.

Morgan Stanley Virtual Asia Pacific Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 24-25, 2020

For more information, please contact your Morgan Stanley representative.

Ardelyx to Participate in Three Upcoming Investor Conferences in September

On September 8, 2020 Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, reported that Ardelyx management will participate in three upcoming investor conferences in September including (Press release, Ardelyx, SEP 8, 2020, View Source [SID1234564785]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9th
22nd Annual H.C. Wainwright Global Investment Conference on Monday, September 14th with a presentation at 5:00 p.m. E.T.
Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday, September 17th with a presentation at 12:40 p.m. E.T.
Both the H.C. Wainwright and Cantor Fitzgerald conference presentations will be available via webcast. To access the live webcasts of Ardelyx’s presentations, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcasts will be available on the Ardelyx website for 30 days following each conference.

Lipocine to Participate in HC Wainwright Annual Global Investment Conference

On September 8, 2020 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conference (Press release, Lipocine, SEP 8, 2020, https://www.prnewswire.com/news-releases/lipocine-to-participate-in-hc-wainwright-annual-global-investment-conference-301124187.html [SID1234564784]). The conference will take place virtually September 14 – 16, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Date:

Monday, September 14

Time:

12 noon Eastern Time

Webcast:

View Source

To register in advance for the conference, refer to View Source

ArcherDX to Participate in Morgan Stanley 18th Annual Global Healthcare Conference

On September 8, 2020 ArcherDX, Inc. reported that Jason Myers, Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 3:45 p.m. Eastern Daylight Time (EDT) / 1:45 p.m. Mountain Daylight Time (MDT) (Press release, ArcherDX, SEP 8, 2020, View Source [SID1234564783]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access a live and archived webcast of the presentation on the "News & Events" section of the company website at View Source

Event

Morgan Stanley 18th Annual Global Healthcare Conference

Presenter

Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX

Date

Monday, September 14

Time

3:45 p.m. EDT

Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference

On September 8, 2020 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, reported that its management is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020 (Press release, Citius Pharmaceuticals, SEP 8, 2020, https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-hc-wainwright-virtual-22nd-annual-global-investment-conference-301124698.html [SID1234564782]). Leonard Mazur, Chairman of Citius, will present on Tuesday, September 15, at 11:00 a.m. Eastern Time where he will deliver a corporate overview of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition he will be providing updates that include the recent expansion of the Company’s intellectual property for Mino-Wrap, a novel approach to reducing post-operative infections associated with surgical implants, future plans to potentially treat and reduce the severity of acute respiratory distress syndrome (ARDS) associated with COVID-19, and Mino-Lok, an antibiotic lock treatment for catheter-related bloodstream infections (CRBSIs), in collaboration with MDACC.

Webcast: View Source

Mr. Mazur will conduct virtual one-on-one meetings with investors during the conference.